Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphoma-Reference-Cited by-同舟云学术

Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphoma

Published:2019-09-03 Issue:1 Volume:23 Page:28-36
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

McBride Ali¹²,Krendyukov Andriy³,Mathieson Nicola³,Campbell Kim⁴,Balu Sanjeev⁴,Natek Maja³,MacDonald Karen⁵,Abraham Ivo²⁵⁶⁷

Affiliation:

1. Banner University Medical Center, Tucson, AZ, USA;

2. University of Arizona Cancer Center, Tucson, AZ, USA;

3. Hexal AG, Holzkirchen, Germany;

4. Sandoz, Princeton, NJ, USA;

5. Matrix45, Tucson, AZ, USA;

6. Center for Health Outcomes and PharmacoEconomic Research, University of Arizona, Tucson, AZ, USA;

7. Colleges of Pharmacy and Medicine, University of Arizona, Tucson, AZ, USA

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2019.1658591

Reference39 articles.

1. A prospective randomised evaluation of G-CSF or G-CSF plus oral antibiotics in chemotherapy-treated patients at high risk of developing febrile neutropenia

2. Risk Models for Predicting Chemotherapy-Induced Neutropenia

3. Impact of Primary Prophylaxis With Granulocyte Colony-Stimulating Factor on Febrile Neutropenia and Mortality in Adult Cancer Patients Receiving Chemotherapy: A Systematic Review

4. Health resource consumption and costs attributable to chemotherapy-induced toxicity in German routine hospital care in lymphoproliferative disorder and NSCLC patients

5. Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Filgrastim biosimilar (EP2006): A review of 15 years’ post-approval evidence;Critical Reviews in Oncology/Hematology;2024-04

2. On-body injector pegfilgrastim for chemotherapy-induced neutropenia prophylaxis: Current Status;Cancer Treatment and Research Communications;2024

3. The status and preparation for the next decade of biosimilars in the Middle Eastern and North African region;Expert Opinion on Biological Therapy;2023-07-26

4. Cost-efficiency analysis and expanded treatment access modeling of conversion to rituximab biosimilars from reference rituximab in Jordan;Journal of Medical Economics;2023-06-30

5. Two decades of pegfilgrastim: what have we learned? Where do we go from here?;Current Medical Research and Opinion;2023-04-08